Agilera Pharma AS Revenue and Competitors
Employee Data
- Agilera Pharma AS has 62 Employees.
- Agilera Pharma AS grew their employee count by 589% last year.
Agilera Pharma AS's People
Name | Title | Email/Phone |
---|
Agilera Pharma AS Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $40.4M | 201 | -9% | N/A | N/A |
#2 | $4.2M | 21 | 11% | N/A | N/A |
#3 | $11.5M | 57 | 2% | N/A | N/A |
#4 | N/A | 62 | 589% | N/A | N/A |
#5 | $14.7M | 73 | 1725% | N/A | N/A |
What Is Agilera Pharma AS?
Agilera is one of the few companies in the world with both expertise and experience in product development and commercial production of radiopharmaceuticals. Our interdisciplinary team promotes technology development and growth by translating research into commercially viable products that improve patient care.Agilera has broad expertise in supporting preclinical and clinical development for new product candidates. Our unique combination of expertise, infrastructure, technology and proximity to the research environments provides the foundation for a seamless and value-creating collaboration with our clients.Agilera is a leading contract development and manufacturing organisation (CDMO). With several decades of experience in the production and distribution of radiopharmaceuticals. The Institute for Energy Technology (IFE) established Agilera as daughter company in 2023.Agilera provides expertise and infrastructure that makes it possible to bring new, innovative radiopharmaceuticals from concept to clinic and onward to commercialisation. In close collaboration with our clients, we will realise the cancer medicine of tomorrow.
keywords:N/AN/A
Total Funding
62
Number of Employees
N/A
Revenue (est)
589%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $7.5M | 89 | -17% | N/A |
#2 | $20M | 95 | 27% | N/A |
#3 | $40.9M | 124 | 22% | N/A |
#4 | $15M | 161 | 5% | N/A |